The 2023 American College of Rheumatology (ACR)/ EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease
Authors' conclusion
The 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.
Study context
- Population
- Patients with joint pain, swelling or tenderness whose symptoms are not fully explained by an alternative disease
- Comparison
- Derivation vs Validation
- Outcome
- Sensitivity and specificity of the 2023 ACR/EULAR CPPD disease classification criteria
Methodological detailsmultinational, multi-criterion decision analysis, independent validation cohort
- Multinational
- Multi-criterion decision analysis
- Independent validation cohort
Performance
As reported in the abstract
Performance of the classification criteria
| Test or model | Sensitivity | Specificity |
|---|---|---|
| Derivation | 92.2% | 87.9% |
| Validation | 99.2% | 92.5% |
Sensitivity
Derivation92.2%
Validation99.2%
Specificity
Derivation87.9%
Validation92.5%
- Otherwise, weighted criteria score classifying as CPPD disease
- >56 points
Original publication
The 2023 ACR/ EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis Rheumatol. Published 26 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →